AcelRx Pharmaceuticals Inc. (ACRX)
Symbol Info
Listed Symbol ACRX
Name AcelRx Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $2,151,000
Latest Fiscal EPS $-0.81
Price Info
21 Day Moving Average $2.3200
21 Day EMA $2.246290
50 Day Moving Average $2.3090
50 Day EMA $2.343510
200 Day EMA $2.683400
200 Day Moving Average 2.751600
52 Week High $5.05
52 Week Low $1.99
52 Week Change $-44.974900
Alpha -0.003240
Beta 2.0731
Standard Deviation 0.239779
R2 0.088245
Periods 60
Share Information
10 Day Average Volume 582,172
20 Day Average Volume 770,178
30 Day Average Volume 732,505
50 Day Average Volume 823,028
Outstanding Shares 79,435,542
Float Shares 77,493,699
Percent Float 97.56%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 152
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 7,534,289
Institute Holdings Percent 33.400000
Institute Sold Previous 3 Months 1,924,983
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,941,843
Price Change
7 Day Price Change $0.0200000
7 Day Percent Change 0.92%
21 Day Price Change $-0.3099999
21 Day Percent Change -12.40%
30 Day Price Change $-0.29
30 Day Percent Change -11.69%
Month To Date Price Change $-0.01
Month To Date Percent -0.45%
90 Day Price Change $-0.59
90 Day Percent Change -21.22%
Quarter To Date $-0.01
Quarter To Date Percent -0.45%
180 Day Price Change $-1.19
180 Day Percent Change -35.21%
200 Day Price Change $-1.03
200 Day Percent Change -31.99%
Year To Date $-0.12
Year To Date Percent -5.19%
Profile
Description AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.
Details
Issue Type CS
Market Cap $173,963,837
Sec Type EQS
Auditor OUM & Co. LLP
Total Shares Outstanding 79,435,542
CEO Vincent J. Angotti
Employees 90
Last Audit UQ
Classification
CIK 0001427925
Industry Medical Devices
Sector Healthcare
NAICS Surgical and Medical Instrument Manufacturing(339112)
Info
Address 351 Galveston Drive
Redwood City, CA 94063
Website http://www.acelrx.com
Facisimile +1 650 216-6500
Telephone +1 650 216-3500
Email investors@acelrx.com
Key Ratios
Profitability
EBIT Margin -2,007.9
EBITDA Margin -1,961.7
Pre-Tax Profit Margin -771.2
Profit Margin Cont -
Gross Margin -134.7
Profit Margin TOT -
Income Statements
Revenue $1,819,000
Revenue Per Share $0.0229
Revenue 3 Years $-48.89
Revenue 5 Years $-30.75
Valuation Measures
PE Ratio -
Enterprise Value $111,980,192
Price To Sales 95.637080
Price To Free Cash -4.8
PE High Last 5 Years -
Price To Book 71.8
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -9.4
Financial Strength
Total Debt To Equity -
Int Coverage -6.3
Current Ratio 11.7
Leverage Ratio 18.4
Quick Ratio 11.1
Long Term Debt To Capital -
Assets
Receivables Turnover 1.8
Invoice Turnover 2.80
Assets Turnover -
Management Effectiveness
Return Assets -57.38
Return On Equity 154.50
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACRX
AcelRX Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.